Evidence map›Paper›PMID 41045992›Full record

ReviewImmunology letters2026

CD4 and CD8 T-cell lymphocytes from penile squamous cell carcinoma tumors are more differentiated with higher PD-1 expression compared to lymphocytes in peripheral circulation.

Chibamba Mumba, Nicholas K Mwale, Victor Mapulanga, Owen Ngalamika

Abstract readReview
In one paragraph

Review in Immunology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chibamba MumbaDepartment of Pathology and Microbiology, University of Zambia School of Medicine, Lusaka, Zambia.
Nicholas K MwaleDepartment of Physiological Sciences, University of Zambia School of Medicine, Lusaka, Zambia.
Victor MapulangaUrology Section, Department of Surgery, University of Zambia School of Medicine, Lusaka, Zambia.
Owen NgalamikaDermatology and Venereology Division, University of Zambia School of Medicine, Lusaka, Zambia. Electronic address: owen_ngalamika@yahoo.com.

Funding

AIDS Malignancies Training and Research International Program (AMTRIP)D43TW010354 · FIC · UNIVERSITY OF NEBRASKA LINCOLN · PI Chipepo Kankasa, Charles Wood · 2016 to 2026
$2.8M
Biomarkers of Kaposi sarcoma recrudescence in ZambiaK43TW011095 · FIC · UNIVERSITY OF ZAMBIA · PI NGALAMIKA, OWEN · 2018 to 2023
$721k
FIC NIH HHS D43 TW010354FIC NIH HHS K43 TW011095
6 · The paper itself

Abstract

backgroundPenile squamous cell carcinoma (PSCC) is the commonest malignancy of the penis, with a higher incidence and poor treatment outcomes in developing countries. T-cell phenotypes have been shown to identify patients who may respond favorably to immune therapy, and also associate with treatment outcomes. This study aimed to determine and compare the tumor and peripheral blood T-cell phenotypes of individuals with PSCC, and whether factors such as smoking and presence of HPV associate with these T-cell phenotypes.

methodsWe conducted a prospective cross-sectional study at the University Teaching Hospital, Lusaka, Zambia. Participants with a histologically-confirmed PSCC were recruited into the study. Socio-demographic information was obtained, and whole blood was collected and subjected to peripheral blood mononuclear cells (PBMCs) isolation. Fresh penile tumors were mechanically and enzymatically digested. CD4 and CD8 cells were sorted from PBMCs and tumor, stained using antibodies against CD3, CD45RO, CCR7, PD-1, CD103 and CD69, and subjected to flow cytometry. Parts of the tumor were subjected to HPV detection, and histological grading and staging.

resultsTwenty-four participants were recruited into the study. The median age was 55.5 years, 45.8 % were smokers, 87.5 % were HIV positive, 62.5 % had high-risk HPV detected in the tumors, and 25 % had advanced-stage disease. There was a significantly higher proportion of naïve cells among CD4 T-cells from PBMCs than tumor (40.2 % vs 3.8 %; p = 0.01). CD4 T cells from the tumor demonstrated a significantly higher proportion of cells expressing CD69 (3.2 % vs 95.9 %; p = 0.0001), CD103 (0.7 % vs 7.3 %; p = 0.0001), and PD-1 (35.5 % vs 92 %; p = 0.0001) than the ones from PBMCs. Tumoral CD8 T-cells had a significantly lower proportion of terminally-differentiated effector cells but higher proportion of central memory cells compared to PBMCs, (7.9 % vs 15.1 %, p = 0.04) and (55 % vs 14.4 %; p = 0.01) respectively. Tumoral CD8 T-cells also had a significantly higher proportion of cells expressing CD69 (96.7 % vs 8.5 %; p = 0.0001), CD103 (22.2 % vs 1.2 %; p = 0.0001), and PD-1 (79.3 % vs 18.8 %; p = 0.0001) when compared to the PBMCs. Early-stage disease was associated with a significantly higher proportion of central memory CD4 T-cells among the PBMCs when compared with advanced stage disease (46.7 % vs 30 %; p = 0.01), while smoking was associated with a significantly higher proportion of tumoral CD8 T-cells expressing the homing marker CD103 (28.2 % vs 17.8 %; p = 0.01).

conclusionPSCC tumors demonstrate a higher proportion of primed T-cells with a memory phenotype compared to T-cells in the circulation. T-cells from PSCC tumors also have a higher proportion of cells expressing the immune checkpoint PD-1 and homing markers than those from the circulation.

Indexed as

Carcinoma, Squamous CellCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesPenile NeoplasmsProgrammed Cell Death 1 ReceptorAdultAgedCell DifferentiationCross-Sectional StudiesHumansImmunophenotypingMaleMiddle AgedNeoplasm StagingProspective StudiesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorImmune checkpointPenile squamous cell carcinomaPeripheral blood mononuclear cellsPhenotypesT cells

Identifiers

PMID41045992
PMCPMC12547531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.